Administration of the adjuvanted pH1N1 vaccine in egg-allergic children at high risk for influenza A/H1N1 disease.
Identifieur interne : 000490 ( Main/Exploration ); précédent : 000489; suivant : 000491Administration of the adjuvanted pH1N1 vaccine in egg-allergic children at high risk for influenza A/H1N1 disease.
Auteurs : Jane E. Schuler [Canada] ; W James King ; Natalie L. Dayneka ; Lynn Rastelli ; Evelyn Marquis ; Zave Chad ; Charles HuiSource :
- Canadian journal of public health = Revue canadienne de sante publique [ 0008-4263 ]
Descripteurs français
- KwdFr :
- Calendrier vaccinal (MeSH), Canada (MeSH), Enfant (MeSH), Enfant d'âge préscolaire (MeSH), Femelle (MeSH), Gestion de la sécurité (MeSH), Grippe humaine (prévention et contrôle), Humains (MeSH), Hypersensibilité à l'oeuf (MeSH), Mâle (MeSH), Nourrisson (MeSH), Sous-type H1N1 du virus de la grippe A (MeSH), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (effets indésirables), Études prospectives (MeSH).
- MESH :
- administration et posologie : Vaccins antigrippaux.
- effets indésirables : Vaccins antigrippaux.
- prévention et contrôle : Grippe humaine.
- Calendrier vaccinal, Canada, Enfant, Enfant d'âge préscolaire, Femelle, Gestion de la sécurité, Humains, Hypersensibilité à l'oeuf, Mâle, Nourrisson, Sous-type H1N1 du virus de la grippe A, Études prospectives.
- Wicri :
- geographic : Canada.
English descriptors
- KwdEn :
- Canada (MeSH), Child (MeSH), Child, Preschool (MeSH), Egg Hypersensitivity (MeSH), Female (MeSH), Humans (MeSH), Immunization Schedule (MeSH), Infant (MeSH), Influenza A Virus, H1N1 Subtype (MeSH), Influenza Vaccines (administration & dosage), Influenza Vaccines (adverse effects), Influenza, Human (prevention & control), Male (MeSH), Prospective Studies (MeSH), Safety Management (MeSH).
- MESH :
- chemical , administration & dosage : Influenza Vaccines.
- chemical , adverse effects : Influenza Vaccines.
- geographic : Canada.
- prevention & control : Influenza, Human.
- Child, Child, Preschool, Egg Hypersensitivity, Female, Humans, Immunization Schedule, Infant, Influenza A Virus, H1N1 Subtype, Male, Prospective Studies, Safety Management.
Abstract
BACKGROUND
In Canada, the pH1N1 influenza vaccine is recommended for children, particularly those less than 5 years of age or with chronic underlying disease. The pH1N1 vaccine, which contains residual allergenic egg white proteins, may pose a risk for vaccination of egg-allergic children.
OBJECTIVE
To describe the outcome of pH1N1 influenza vaccine administration to egg-allergic children at risk for severe H1N1 disease.
DESIGN/METHOD
Prospective observational cohort study. Children identified as at high risk for egg allergy and H1N1 influenza were vaccinated using a two-dose split protocol in a controlled medical setting. Children were given an initial test dose; if no reaction was noted, the remainder of the dose was administered and the children were followed for allergic reactions. Those who tolerated the split dose and required a second dose of vaccine were offered vaccination four weeks later as one injection.
RESULTS
Sixty-two egg-allergic children considered at high risk for H1N1 disease received the adjuvanted pH1N1 vaccine. Egg allergy was diagnosed both clinically by an allergist and using skin and/or serum IgE testing. Within one hour of immunization, 2 children developed hives, 1 had a vasovagal response and 1 had a hypo-responsive episode. Fourteen children received the second H1N1 dose and 1 developed erythema and itching. There were no anaphylactic reactions.
CONCLUSION
Administration of the adjuvanted pH1N1 vaccine in egg-allergic children at risk for severe H1N1 influenza was safe when performed in a two-dose split protocol in a controlled medical setting.
PubMed: 21714318
PubMed Central: PMC6973565
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Administration of the adjuvanted pH1N1 vaccine in egg-allergic children at high risk for influenza A/H1N1 disease.</title><author><name sortKey="Schuler, Jane E" sort="Schuler, Jane E" uniqKey="Schuler J" first="Jane E" last="Schuler">Jane E. Schuler</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Faculty of Medicine, University of Ottawa, Ottawa, ON. jschuler@cheo.on.ca</nlm:affiliation><country wicri:rule="url">Canada</country></affiliation></author><author><name sortKey="King, W James" sort="King, W James" uniqKey="King W" first="W James" last="King">W James King</name></author><author><name sortKey="Dayneka, Natalie L" sort="Dayneka, Natalie L" uniqKey="Dayneka N" first="Natalie L" last="Dayneka">Natalie L. Dayneka</name></author><author><name sortKey="Rastelli, Lynn" sort="Rastelli, Lynn" uniqKey="Rastelli L" first="Lynn" last="Rastelli">Lynn Rastelli</name></author><author><name sortKey="Marquis, Evelyn" sort="Marquis, Evelyn" uniqKey="Marquis E" first="Evelyn" last="Marquis">Evelyn Marquis</name></author><author><name sortKey="Chad, Zave" sort="Chad, Zave" uniqKey="Chad Z" first="Zave" last="Chad">Zave Chad</name></author><author><name sortKey="Hui, Charles" sort="Hui, Charles" uniqKey="Hui C" first="Charles" last="Hui">Charles Hui</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2011">2011 May-Jun</date><idno type="RBID">pubmed:21714318</idno><idno type="pmid">21714318</idno><idno type="pmc">PMC6973565</idno><idno type="wicri:Area/Main/Corpus">000525</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000525</idno><idno type="wicri:Area/Main/Curation">000525</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000525</idno><idno type="wicri:Area/Main/Exploration">000525</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Administration of the adjuvanted pH1N1 vaccine in egg-allergic children at high risk for influenza A/H1N1 disease.</title><author><name sortKey="Schuler, Jane E" sort="Schuler, Jane E" uniqKey="Schuler J" first="Jane E" last="Schuler">Jane E. Schuler</name><affiliation wicri:level="1"><nlm:affiliation>Department of Pediatrics, Faculty of Medicine, University of Ottawa, Ottawa, ON. jschuler@cheo.on.ca</nlm:affiliation><country wicri:rule="url">Canada</country></affiliation></author><author><name sortKey="King, W James" sort="King, W James" uniqKey="King W" first="W James" last="King">W James King</name></author><author><name sortKey="Dayneka, Natalie L" sort="Dayneka, Natalie L" uniqKey="Dayneka N" first="Natalie L" last="Dayneka">Natalie L. Dayneka</name></author><author><name sortKey="Rastelli, Lynn" sort="Rastelli, Lynn" uniqKey="Rastelli L" first="Lynn" last="Rastelli">Lynn Rastelli</name></author><author><name sortKey="Marquis, Evelyn" sort="Marquis, Evelyn" uniqKey="Marquis E" first="Evelyn" last="Marquis">Evelyn Marquis</name></author><author><name sortKey="Chad, Zave" sort="Chad, Zave" uniqKey="Chad Z" first="Zave" last="Chad">Zave Chad</name></author><author><name sortKey="Hui, Charles" sort="Hui, Charles" uniqKey="Hui C" first="Charles" last="Hui">Charles Hui</name></author></analytic><series><title level="j">Canadian journal of public health = Revue canadienne de sante publique</title><idno type="ISSN">0008-4263</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Canada (MeSH)</term><term>Child (MeSH)</term><term>Child, Preschool (MeSH)</term><term>Egg Hypersensitivity (MeSH)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Immunization Schedule (MeSH)</term><term>Infant (MeSH)</term><term>Influenza A Virus, H1N1 Subtype (MeSH)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (adverse effects)</term><term>Influenza, Human (prevention & control)</term><term>Male (MeSH)</term><term>Prospective Studies (MeSH)</term><term>Safety Management (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Calendrier vaccinal (MeSH)</term><term>Canada (MeSH)</term><term>Enfant (MeSH)</term><term>Enfant d'âge préscolaire (MeSH)</term><term>Femelle (MeSH)</term><term>Gestion de la sécurité (MeSH)</term><term>Grippe humaine (prévention et contrôle)</term><term>Humains (MeSH)</term><term>Hypersensibilité à l'oeuf (MeSH)</term><term>Mâle (MeSH)</term><term>Nourrisson (MeSH)</term><term>Sous-type H1N1 du virus de la grippe A (MeSH)</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (effets indésirables)</term><term>Études prospectives (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Canada</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Child</term><term>Child, Preschool</term><term>Egg Hypersensitivity</term><term>Female</term><term>Humans</term><term>Immunization Schedule</term><term>Infant</term><term>Influenza A Virus, H1N1 Subtype</term><term>Male</term><term>Prospective Studies</term><term>Safety Management</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Calendrier vaccinal</term><term>Canada</term><term>Enfant</term><term>Enfant d'âge préscolaire</term><term>Femelle</term><term>Gestion de la sécurité</term><term>Humains</term><term>Hypersensibilité à l'oeuf</term><term>Mâle</term><term>Nourrisson</term><term>Sous-type H1N1 du virus de la grippe A</term><term>Études prospectives</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>In Canada, the pH1N1 influenza vaccine is recommended for children, particularly those less than 5 years of age or with chronic underlying disease. The pH1N1 vaccine, which contains residual allergenic egg white proteins, may pose a risk for vaccination of egg-allergic children.</p></div><div type="abstract" xml:lang="en"><p><b>OBJECTIVE</b></p><p>To describe the outcome of pH1N1 influenza vaccine administration to egg-allergic children at risk for severe H1N1 disease.</p></div><div type="abstract" xml:lang="en"><p><b>DESIGN/METHOD</b></p><p>Prospective observational cohort study. Children identified as at high risk for egg allergy and H1N1 influenza were vaccinated using a two-dose split protocol in a controlled medical setting. Children were given an initial test dose; if no reaction was noted, the remainder of the dose was administered and the children were followed for allergic reactions. Those who tolerated the split dose and required a second dose of vaccine were offered vaccination four weeks later as one injection.</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>Sixty-two egg-allergic children considered at high risk for H1N1 disease received the adjuvanted pH1N1 vaccine. Egg allergy was diagnosed both clinically by an allergist and using skin and/or serum IgE testing. Within one hour of immunization, 2 children developed hives, 1 had a vasovagal response and 1 had a hypo-responsive episode. Fourteen children received the second H1N1 dose and 1 developed erythema and itching. There were no anaphylactic reactions.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSION</b></p><p>Administration of the adjuvanted pH1N1 vaccine in egg-allergic children at risk for severe H1N1 influenza was safe when performed in a two-dose split protocol in a controlled medical setting.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">21714318</PMID><DateCompleted><Year>2011</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2020</Year><Month>02</Month><Day>05</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0008-4263</ISSN><JournalIssue CitedMedium="Print"><Volume>102</Volume><Issue>3</Issue><PubDate><MedlineDate>2011 May-Jun</MedlineDate></PubDate></JournalIssue><Title>Canadian journal of public health = Revue canadienne de sante publique</Title><ISOAbbreviation>Can J Public Health</ISOAbbreviation></Journal><ArticleTitle>Administration of the adjuvanted pH1N1 vaccine in egg-allergic children at high risk for influenza A/H1N1 disease.</ArticleTitle><Pagination><MedlinePgn>196-9</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In Canada, the pH1N1 influenza vaccine is recommended for children, particularly those less than 5 years of age or with chronic underlying disease. The pH1N1 vaccine, which contains residual allergenic egg white proteins, may pose a risk for vaccination of egg-allergic children.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To describe the outcome of pH1N1 influenza vaccine administration to egg-allergic children at risk for severe H1N1 disease.</AbstractText><AbstractText Label="DESIGN/METHOD" NlmCategory="METHODS">Prospective observational cohort study. Children identified as at high risk for egg allergy and H1N1 influenza were vaccinated using a two-dose split protocol in a controlled medical setting. Children were given an initial test dose; if no reaction was noted, the remainder of the dose was administered and the children were followed for allergic reactions. Those who tolerated the split dose and required a second dose of vaccine were offered vaccination four weeks later as one injection.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Sixty-two egg-allergic children considered at high risk for H1N1 disease received the adjuvanted pH1N1 vaccine. Egg allergy was diagnosed both clinically by an allergist and using skin and/or serum IgE testing. Within one hour of immunization, 2 children developed hives, 1 had a vasovagal response and 1 had a hypo-responsive episode. Fourteen children received the second H1N1 dose and 1 developed erythema and itching. There were no anaphylactic reactions.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Administration of the adjuvanted pH1N1 vaccine in egg-allergic children at risk for severe H1N1 influenza was safe when performed in a two-dose split protocol in a controlled medical setting.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Schuler</LastName><ForeName>Jane E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Faculty of Medicine, University of Ottawa, Ottawa, ON. jschuler@cheo.on.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>King</LastName><ForeName>W James</ForeName><Initials>WJ</Initials></Author><Author ValidYN="Y"><LastName>Dayneka</LastName><ForeName>Natalie L</ForeName><Initials>NL</Initials></Author><Author ValidYN="Y"><LastName>Rastelli</LastName><ForeName>Lynn</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Marquis</LastName><ForeName>Evelyn</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Chad</LastName><ForeName>Zave</ForeName><Initials>Z</Initials></Author><Author ValidYN="Y"><LastName>Hui</LastName><ForeName>Charles</ForeName><Initials>C</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Can J Public Health</MedlineTA><NlmUniqueID>0372714</NlmUniqueID><ISSNLinking>0008-4263</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D021181" MajorTopicYN="Y">Egg Hypersensitivity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007115" MajorTopicYN="N">Immunization Schedule</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053118" MajorTopicYN="Y">Influenza A Virus, H1N1 Subtype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017751" MajorTopicYN="N">Safety Management</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>7</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21714318</ArticleId><ArticleId IdType="pmc">PMC6973565</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lancet. 2009 Aug 22;374(9690):605-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19700000</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pediatr. 1985 Jun;106(6):931-3</Citation><ArticleIdList><ArticleId IdType="pubmed">3998949</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatrics. 2003 Oct;112(4):815-20</Citation><ArticleIdList><ArticleId IdType="pubmed">14523172</ArticleId></ArticleIdList></Reference><Reference><Citation>Am J Epidemiol. 1980 Mar;111(3):270-8</Citation><ArticleIdList><ArticleId IdType="pubmed">7361749</ArticleId></ArticleIdList></Reference><Reference><Citation>Lancet. 2009 Aug 22;374(9690):605</Citation><ArticleIdList><ArticleId IdType="pubmed">19700001</ArticleId></ArticleIdList></Reference><Reference><Citation>J Infect Dis. 1977 Dec;136 Suppl:S652-5</Citation><ArticleIdList><ArticleId IdType="pubmed">564376</ArticleId></ArticleIdList></Reference><Reference><Citation>J Pediatr. 1998 Nov;133(5):624-8</Citation><ArticleIdList><ArticleId IdType="pubmed">9821418</ArticleId></ArticleIdList></Reference><Reference><Citation>BMJ. 2009 Sep 15;339:b3680</Citation><ArticleIdList><ArticleId IdType="pubmed">19755545</ArticleId></ArticleIdList></Reference><Reference><Citation>Arch Pediatr Adolesc Med. 2010 Jan;164(1):24-30</Citation><ArticleIdList><ArticleId IdType="pubmed">20048238</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaccine. 2008 Aug 26;26(36):4664-8</Citation><ArticleIdList><ArticleId IdType="pubmed">18639601</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2009 Nov 12;361(20):1935-44</Citation><ArticleIdList><ArticleId IdType="pubmed">19815859</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2009 Sep 4;58(34):941-7</Citation><ArticleIdList><ArticleId IdType="pubmed">19730406</ArticleId></ArticleIdList></Reference><Reference><Citation>J Allergy Clin Immunol. 2007 Sep;120(3):638-46</Citation><ArticleIdList><ArticleId IdType="pubmed">17628647</ArticleId></ArticleIdList></Reference><Reference><Citation>N Engl J Med. 2010 Jan 7;362(1):45-55</Citation><ArticleIdList><ArticleId IdType="pubmed">20032320</ArticleId></ArticleIdList></Reference><Reference><Citation>Ann Allergy. 1992 Jan;68(1):69</Citation><ArticleIdList><ArticleId IdType="pubmed">1736722</ArticleId></ArticleIdList></Reference><Reference><Citation>Curr Allergy Asthma Rep. 2006 Mar;6(2):145-52</Citation><ArticleIdList><ArticleId IdType="pubmed">16566865</ArticleId></ArticleIdList></Reference><Reference><Citation>MMWR Morb Mortal Wkly Rep. 2009 Aug 28;58(33):913-8</Citation><ArticleIdList><ArticleId IdType="pubmed">19713879</ArticleId></ArticleIdList></Reference><Reference><Citation>CMAJ. 2010 Jan 12;182(1):39-44</Citation><ArticleIdList><ArticleId IdType="pubmed">19926677</ArticleId></ArticleIdList></Reference><Reference><Citation>Pediatr Pulmonol. 2007 Jun;42(6):489-95</Citation><ArticleIdList><ArticleId IdType="pubmed">17469157</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Chad, Zave" sort="Chad, Zave" uniqKey="Chad Z" first="Zave" last="Chad">Zave Chad</name><name sortKey="Dayneka, Natalie L" sort="Dayneka, Natalie L" uniqKey="Dayneka N" first="Natalie L" last="Dayneka">Natalie L. Dayneka</name><name sortKey="Hui, Charles" sort="Hui, Charles" uniqKey="Hui C" first="Charles" last="Hui">Charles Hui</name><name sortKey="King, W James" sort="King, W James" uniqKey="King W" first="W James" last="King">W James King</name><name sortKey="Marquis, Evelyn" sort="Marquis, Evelyn" uniqKey="Marquis E" first="Evelyn" last="Marquis">Evelyn Marquis</name><name sortKey="Rastelli, Lynn" sort="Rastelli, Lynn" uniqKey="Rastelli L" first="Lynn" last="Rastelli">Lynn Rastelli</name></noCountry><country name="Canada"><noRegion><name sortKey="Schuler, Jane E" sort="Schuler, Jane E" uniqKey="Schuler J" first="Jane E" last="Schuler">Jane E. Schuler</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeCanadaV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000490 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000490 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeCanadaV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:21714318
|texte= Administration of the adjuvanted pH1N1 vaccine in egg-allergic children at high risk for influenza A/H1N1 disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:21714318" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV4
| This area was generated with Dilib version V0.6.35. |  |